Winston Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Winston Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Winston Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Winston Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Winston Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Winston Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

• Winston Pharmaceuticals, Inc. - Brief Winston Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
• Review of current pipeline of Winston Pharmaceuticals, Inc. human therapeutic division.
• Overview of pipeline therapeutics across various therapy areas.
• Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
• Product profiles for late stage and clinical stage products of Winston Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
• Recent updates of the Winston Pharmaceuticals, Inc.’s pipeline in the last quarter.
• Key discontinued and dormant projects.
• Latest news and deals relating to the products.

Reasons to buy

• Evaluate Winston Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
• Assess the growth potential of Winston Pharmaceuticals, Inc. in its therapy areas of focus.
• Identify new drug targets and therapeutic classes in the Winston Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
• Exploit collaboration and partnership opportunities with Winston Pharmaceuticals, Inc..
• Avoid Intellectual Property Rights related issues.
• Explore the dormant and discontinued projects of Winston Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Contents

Winston Pharmaceuticals, Inc. Snapshot
Winston Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Winston Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Winston Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Winston Pharmaceuticals, Inc. – Pipeline Products Glance
Winston Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Winston Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Winston Pharmaceuticals, Inc. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Winston Pharmaceuticals, Inc. – Drug Profiles
Civamide Nasal Solution
Civamide Patch
Civamide Sterile Solution
Civanex
Dolorac
Intra-Articular Civamide
Winston Pharmaceuticals, Inc. – Pipeline Analysis
Winston Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Winston Pharmaceuticals, Inc. - Pipeline Products By Target
Winston Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Winston Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Winston Pharmaceuticals, Inc. – Recent Pipeline Updates
Winston Pharmaceuticals, Inc. - Dormant Projects
Winston Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Company's Recent Developments
Winston Pharmaceuticals, Inc., Recent Developments
Nov 22, 2010: Winston Announces Positive Results From Phase II Clinical Trial Of Dolorac Nasal Solution
Jul 20, 2010: Winston Receives Notice Of Compliance In Canada For CIVANEX For Treatment Of Osteoarthritis
Jul 07, 2010: Winston Laboratories Submits NDA For CIVANEX For Treatment Of Osteoarthritis
Financial Deals Landscape
Winston Pharmaceuticals, Inc., Deals Summary
Winston Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
Sanofi-Aventis Enters Into Licensing Agreement With Winston Laboratories
Sirius Laboratories Extends Its Licensing Agreement With Winston Laboratories
Winston Laboratories Enters Into Licensing Agreement With Opko Ophthalmologics
Winston Laboratories Enters Into Licensing Agreement With Exopharma
Sirius Laboratories Enters Into Licensing Agreement With Winston Laboratories
Acquisition
Winston Laboratories Acquires Getting Ready
Winston Laboratories Acquires Minority Stake In Rodlen From Bioglan Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Winston Pharmaceuticals, Inc., Key Information
Winston Pharmaceuticals, Inc., Key Facts
Winston Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Winston Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Winston Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Winston Pharmaceuticals, Inc. – Filed, H2 2011
Winston Pharmaceuticals, Inc. – Phase III, H2 2011
Winston Pharmaceuticals, Inc. - Phase II, H2 2011
Winston Pharmaceuticals, Inc. - Phase I, H2 2011
Winston Pharmaceuticals, Inc. – Pre-Clinical, H2 2011
Winston Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Winston Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Winston Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Winston Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Winston Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Winston Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Winston Pharmaceuticals, Inc., Subsidiaries
Winston Pharmaceuticals, Inc., Deals Summary
Sanofi-Aventis Enters Into Licensing Agreement With Winston Laboratories
Sirius Laboratories Extends Its Licensing Agreement With Winston Laboratories
Winston Laboratories Enters Into Licensing Agreement With Opko Ophthalmologics
Winston Laboratories Enters Into Licensing Agreement With Exopharma
Sirius Laboratories Enters Into Licensing Agreement With Winston Laboratories
Winston Laboratories Acquires Getting Ready
Winston Laboratories Acquires Minority Stake In Rodlen From Bioglan Pharma

LIST OF FIGURES

Winston Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Winston Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Winston Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Winston Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Winston Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011 Skip to top